Turtle Creek Wealth Advisors LLC Acquires Shares of 4,489 Gilead Sciences, Inc. $GILD

Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,489 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the first quarter valued at $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. Finally, Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 241 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,000 shares of company stock worth $7,986,340. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of GILD stock opened at $117.85 on Friday. The stock has a 50-day moving average price of $115.15 and a 200 day moving average price of $110.45. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a market cap of $146.23 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 0.81 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $85.60 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Ratings Changes

A number of analysts have recently weighed in on GILD shares. Royal Bank Of Canada raised their target price on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Cantor Fitzgerald raised their target price on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $118.65.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.